HLA-C and cancer: Moreover, because the frequency of MHC alleles varies across different human subpopulations (19), there is substantial danger that differing MHC–peptide prediction performance across alleles may yield disparate outcomes in immunotherapies across racial and ethnic groups, thereby exacerbating the already significant disparities in cancer mortality and treatment across racial groups (20).